1. Yiin, GSC, Li, L, Bejot, Y, et al. Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation. Stroke 2019; 50: 21–27. DOI: 10.1161/STROKEAHA.118.022249.
Google Scholar | Crossref2. Sposato, LA, Cipriano, LE, Saposnik, G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. The Lancet Neurology 2015; 14: 377–387. DOI: 10.1016/S1474-4422(15)70027-X.
Google Scholar | Crossref | Medline | ISI3. Hart, RG, Pearce, LA, Aguilar, MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867. 2007/06/20. DOI: 10.7326/0003-4819-146-12-200706190-00007.
Google Scholar | Crossref | Medline | ISI4. Diener, HC, Hankey, GJ, Easton, JD, et al. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2020; 22: I13–i21. 2020/10/24. DOI: 10.1093/eurheartj/suaa104.
Google Scholar | Crossref | Medline5. Salazar, CA, del Aguila, D, Cordova, EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014; 27: Cd009893. 2014/03/29. DOI: 10.1002/14651858.CD009893.pub2.
Google Scholar | Crossref6. Bruins Slot, KM, Berge, E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2018; 3: Cd008980.2018/03/07. DOI: 10.1002/14651858.CD008980.pub3.
Google Scholar | Crossref | Medline7. Seiffge, DJ, Paciaroni, M, Wilson, D, et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol 2019; 85: 823–834. 2019/04/14. DOI: 10.1002/ana.25489.
Google Scholar | Crossref | Medline8. Hart, RG, Coull, BM, Hart, D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 1983; 14: 688–693. 1983/09/01. DOI: 10.1161/01.str.14.5.688.
Google Scholar | Crossref | Medline9. Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine 2009; 361: 1139–1151. DOI: 10.1056/NEJMoa0905561.
Google Scholar | Crossref | Medline | ISI10. Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine 2011; 365: 883–891. DOI: 10.1056/NEJMoa1009638.
Google Scholar | Crossref | Medline | ISI11. Granger, CB, Alexander, JH, McMurray, JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine 2011; 365: 981–992. DOI: 10.1056/NEJMoa1107039.
Google Scholar | Crossref | Medline | ISI12. Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2013; 369: 2093–2104. DOI: 10.1056/NEJMoa1310907.
Google Scholar | Crossref | Medline | ISI13. Diener, HC, Ntaios, G, O'Donnell, M, et al. Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke. Expert Opin Pharmacother 2018; 19: 1597–1602. 2018/08/29. DOI: 10.1080/14656566.2018.1515913.
Google Scholar | Crossref | Medline14. Labovitz, AJ, Rose, DZ, Fradley, MG, et al. Early Apixaban use following stroke in patients with atrial fibrillation: results of the AREST trial. Stroke 2021; 52: 1164–1171. 2021/02/26. DOI: 10.1161/STROKEAHA.120.030042.
Google Scholar | Crossref | Medline15. Paciaroni, M, Agnelli, G, Falocci, N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 2015; 46: 2175–2182. 2015/07/02. DOI: 10.1161/STROKEAHA.115.008891.
Google Scholar | Crossref | Medline | ISI16. Yaghi, S, Trivedi, T, Henninger, N, et al. Anticoagulation timing in cardioembolic stroke and recurrent event risk. Ann Neurol 2020; 88: 807–816. 2020/07/14. DOI: 10.1002/ana.25844.
Google Scholar | Crossref | Medline17. Klijn, CJ, Paciaroni, M, Berge, E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European stroke organisation guideline. Eur Stroke J 2019; 4: 198–223. 2020/01/28. DOI: 10.1177/2396987319841187.
Google Scholar | SAGE Journals | ISI18. Steffel, J, Verhamme, P, Potpara, TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 2018; 39: 1330–1393. DOI: 10.1093/eurheartj/ehy136.
Google Scholar | Crossref | Medline19. Powers, WJ, Rabinstein, AA, Ackerson, T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2019; 50: e344–e418. 2019/10/31. DOI: 10.1161/str.0000000000000211.
Google Scholar | Crossref | Medline20. Kleindorfer, DO, Towfighi, A, Chaturvedi, S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke; 0: STR.0000000000000375. DOI: 10.1161/STR.0000000000000375.
Google Scholar | Crossref21. Rybinnik, I, Wong, S, Mehta, D, et al. Anticoagulation Choice and Timing in Stroke Due to Atrial Fibrillation: A Survey of US Stroke Specialists (ACT-SAFe). J Stroke Cerebrovasc Dis 2020; 29: 105169. 2020/09/12. DOI: 10.1016/j.jstrokecerebrovasdis.2020.105169.
Google Scholar | Crossref | Medline22. Munn, D, Abdul-Rahim, AH, Fischer, U, et al. A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation? Eur Stroke J 2018; 3: 355–360. 2019/06/27. DOI: 10.1177/2396987318787124.
Google Scholar | SAGE Journals | ISI23. Textor, J, van der Zander, B, Gilthorpe, MS, et al. Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. International Journal of Epidemiology 2017; 45: 1887–1894. DOI: 10.1093/ije/dyw341.
Google Scholar | Crossref24. Wilson, D, Ambler, G, Banerjee, G, et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. Journal of Neurology, Neurosurgery & Psychiatry 2019; 90: 320–325. DOI: 10.1136/jnnp-2018-318890.
Google Scholar | Crossref | Medline25. Mizoguchi, T, Tanaka, K, Toyoda, K, et al. Early initiation of direct oral anticoagulants after onset of stroke and short- and long-term outcomes of patients with nonvalvular atrial fibrillation. Stroke 2020; 51: 883–891. 2020/01/23. DOI: 10.1161/strokeaha.119.028118.
Google Scholar | Crossref | Medline26. Marsh, EB, Llinas, RH, Hillis, AE, et al. Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation. European Journal of Neurology 2013; 20: 962–967. DOI: 10.1111/ene.12126.
Google Scholar | Crossref | Medline27. Paciaroni, M, Agnelli, G, Ageno, W, et al. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thrombosis and Haemostasis 2017; 116: 410–416. DOI: 10.1160/th16-03-0217.
Google Scholar | Crossref28. Toyoda, K, Yasaka, M, Uchiyama, S, et al. CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study. Hypertens Res 2014; 37: 463–466. 2013/11/08. DOI: 10.1038/hr.2013.150.
Google Scholar | Crossref | Medline29. Yaghi, S, Henninger, N, Scher, E, et al. Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study. J Neurol Neurosurg Psychiatry 2020; 91: 750–755. 2020/05/15. DOI: 10.1136/jnnp-2020-323041.
Google Scholar | Crossref | Medline30. Mac Grory, B, Flood, S, Schrag, M, et al. Anticoagulation Resumption After Stroke from Atrial Fibrillation. Curr Atheroscler Rep 2019; 21: 29. 2019/05/22. DOI: 10.1007/s11883-019-0790-x.
Google Scholar | Crossref | Medline31. Haas, K, Purrucker, JC, Rizos, T, et al. Rationale and design of the registry of acute stroke under novel oral anticoagulants-prime (RASUNOA-prime). European Stroke Journal 2019; 4: 181–188. DOI: 10.1177/2396987318812644.
Google Scholar | SAGE Journals | ISI32. King, BT, Lawrence, PD, Milling, TJ, et al. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. International Journal of Stroke 2019; 14: 977–982. DOI: 10.1177/1747493019870651.
Google Scholar | SAGE Journals | ISI33. Asberg, S, Hijazi, Z, Norrving, B, et al. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials 2017; 18: 581. 2017/12/05. DOI: 10.1186/s13063-017-2313-9.
Google Scholar | Crossref | Medline34. Late Breaking Abstracts. European Stroke Journal 2021; 6: 514–543. DOI: 10.1177/23969873211044666.
Google Scholar | SAGE Journals